Title:
AMELIORATING AGENT FOR LEUKEMIA
Document Type and Number:
WIPO Patent Application WO/2019/035241
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing an ameliorating agent for leukemia that uses an antibody. The problem is solved by an ameliorating agent for leukemia containing an anti-endoglin antibody.
Inventors:
SONODA YOSHIAKI (JP)
FUJIOKA TATSUYA (JP)
MATSUOKA YOSHIKAZU (JP)
FUJIOKA TATSUYA (JP)
MATSUOKA YOSHIKAZU (JP)
Application Number:
PCT/JP2018/014494
Publication Date:
February 21, 2019
Filing Date:
April 04, 2018
Export Citation:
Assignee:
KANSAI MEDICAL UNIV EDUCATIONAL CORPORATION (JP)
International Classes:
A61K39/395; A61K45/00; A61K47/51; A61K47/68; A61K51/10; A61P7/00; A61P35/02; A61P43/00
Foreign References:
| JP2017506234A | 2017-03-02 | |||
| JP2013506677A | 2013-02-28 |
Other References:
DOURADO, K. M. C. ET AL.: "Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models", BLOOD, vol. 129, no. 18, May 2017 (2017-05-01), pages 2526 - 2536, XP055575174, ISSN: 0006-4971
DOURADO, K. M. C . ET AL.: "Endoglin ( CD105) in AML: a potential novel target for therapeutic intervention", BLOOD, vol. 128, 2016, pages 5211, ISSN: 0006-4971, Retrieved from the Internet [retrieved on 20180621]
GOUGOS, A. ET AL.: "Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts", INT. IMMUNOL., vol. 4, no. 1, 1992, pages 83 - 92, XP000886023, ISSN: 0953-8178
POREBA, M. ET AL.: "Expression of CD105 antigen in patients with acute leukemia, malignant lymphoma, and multiple myeloma in active phase of the disease", ADV. CLIN. EXP. MED., vol. 15, no. 6, January 2006 (2006-01-01), pages 1023 - 1028, XP055575182, ISSN: 1230-025X
VRBACKY, F. ET AL.: "Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia", NEOPLASMA, vol. 61, no. 5, 2014, pages 585 - 592, XP055575183, ISSN: 0028-2685
DOURADO, K. M. C . ET AL.: "Endoglin ( CD105) in AML: a potential novel target for therapeutic intervention", BLOOD, vol. 128, 2016, pages 5211, ISSN: 0006-4971, Retrieved from the Internet
GOUGOS, A. ET AL.: "Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts", INT. IMMUNOL., vol. 4, no. 1, 1992, pages 83 - 92, XP000886023, ISSN: 0953-8178
POREBA, M. ET AL.: "Expression of CD105 antigen in patients with acute leukemia, malignant lymphoma, and multiple myeloma in active phase of the disease", ADV. CLIN. EXP. MED., vol. 15, no. 6, January 2006 (2006-01-01), pages 1023 - 1028, XP055575182, ISSN: 1230-025X
VRBACKY, F. ET AL.: "Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia", NEOPLASMA, vol. 61, no. 5, 2014, pages 585 - 592, XP055575183, ISSN: 0028-2685
Attorney, Agent or Firm:
SAEGUSA & PARTNERS (JP)
Download PDF: